Press release
| [ BoxID 200405, Biotechnology ] Roche´s xCELLigence System Offers Dynamic and Label-free Assessing of Kinase Activity in Living Cells![]() Roche´s xCELLigence System Offers Dynamic and Label-free Assessing of Kinase Activity in Living Cells (pressebox) Mannheim, 28.08.2008 - The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities. The electrical impedance detection method with Roche's real-time cell microelectronic sensor-based platform xCELLigence system is a facile, high content, and cell based kinase assay allowing for monitoring short term RTK activation and the long term biologic effect of the activation in real time in a single well. The novel technology has improved utility over existing in vitro and cell based assay in the identification and characterization of selective and potent kinase inhibitors, as shown in a recent study. Contact person: Mr. Dr. Burkhard Ziebolz About Roche Diagnostics GmbH:
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
LIGHTCYCLER and REALTIME READY are trademarks of Roche. |
![]()
Futher press releases 21. Nov, 2008 20. Nov, 2008 19. Nov, 2008 19. Nov, 2008 19. Nov, 2008 14. Nov, 2008 11. Nov, 2008 06. Nov, 2008 |
|
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton und Informationsmaterialien. Die Huber Verlag für Neue Medien GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. |
partners: seminarSPIEGEL|Initiative Middle Class|ititpro.com|promago.de|aktiv-verzeichnis.de |LifePR.de



back to homepage


